MX2023004221A - Inhibidores de rad51. - Google Patents
Inhibidores de rad51.Info
- Publication number
- MX2023004221A MX2023004221A MX2023004221A MX2023004221A MX2023004221A MX 2023004221 A MX2023004221 A MX 2023004221A MX 2023004221 A MX2023004221 A MX 2023004221A MX 2023004221 A MX2023004221 A MX 2023004221A MX 2023004221 A MX2023004221 A MX 2023004221A
- Authority
- MX
- Mexico
- Prior art keywords
- rad51
- inhibitors
- rad51 inhibitors
- directed
- represented
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001195 RAD51 Human genes 0.000 abstract 1
- 108010068097 Rad51 Recombinase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta solicitud se dirige a inhibidores de RAD51 representados por la siguiente fórmula estructural, (ver Fórmula); y métodos para su uso, tales como para tratar el cáncer, enfermedades autoinmunitarias, deficiencias inmunitarias, o enfermedades neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556763P | 2017-09-11 | 2017-09-11 | |
| US201862711959P | 2018-07-30 | 2018-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004221A true MX2023004221A (es) | 2023-04-21 |
Family
ID=63722779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002745A MX2020002745A (es) | 2017-09-11 | 2018-09-11 | Inhibidores de rad51. |
| MX2023004221A MX2023004221A (es) | 2017-09-11 | 2020-03-11 | Inhibidores de rad51. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002745A MX2020002745A (es) | 2017-09-11 | 2018-09-11 | Inhibidores de rad51. |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10590122B2 (es) |
| EP (2) | EP3681884B1 (es) |
| JP (1) | JP7265537B2 (es) |
| KR (1) | KR102718671B1 (es) |
| CN (1) | CN111542521B (es) |
| AU (1) | AU2018328818C1 (es) |
| BR (1) | BR112020004828A2 (es) |
| CA (1) | CA3075062A1 (es) |
| DK (1) | DK3681884T3 (es) |
| ES (1) | ES2925218T3 (es) |
| HU (1) | HUE059969T2 (es) |
| IL (2) | IL273156B (es) |
| MX (2) | MX2020002745A (es) |
| PH (1) | PH12020550079A1 (es) |
| PL (1) | PL3681884T3 (es) |
| PT (1) | PT3681884T (es) |
| SG (2) | SG11202002069WA (es) |
| SI (1) | SI3681884T1 (es) |
| TW (1) | TWI791608B (es) |
| WO (1) | WO2019051465A1 (es) |
| ZA (1) | ZA202104029B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| CN111542521B (zh) | 2017-09-11 | 2024-02-23 | 赛泰尔治疗公司 | Rad51抑制剂 |
| BR112021017336A2 (pt) * | 2019-03-12 | 2021-11-09 | Cyteir Therapeutics Inc | Inibidores de rad51 |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| US12064419B2 (en) * | 2019-06-21 | 2024-08-20 | Cyteir Therapeutics, Inc. | Methods of using RAD51 inhibitors for treatment of pancreatic cancer |
| WO2021164746A1 (zh) | 2020-02-19 | 2021-08-26 | 江苏先声药业有限公司 | 取代芳基类化合物 |
| TW202146014A (zh) * | 2020-03-03 | 2021-12-16 | 美商賽堤爾醫療公司 | 靶向同源重組：新合成致死性治療範例 |
| WO2022081584A1 (en) * | 2020-10-13 | 2022-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to predict outcomes to chimeric antigen receptor t-cells in lymphoma from cell-free dna and genetic mutations |
| JP2022151436A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 髄膜炎と脳炎の治療薬。 |
| CN116063243A (zh) * | 2021-11-02 | 2023-05-05 | 上海旭成医药科技有限公司 | 芳香化合物、其制备方法、中间体、药物组合物和应用 |
| CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
| WO2025038484A1 (en) * | 2023-08-11 | 2025-02-20 | Cyteir Therapeutics, Inc. | Method for preparing cyclohexyl thiazolyl phenyl carbamate |
| CN117603097B (zh) * | 2023-11-29 | 2024-06-18 | 安徽泽升科技股份有限公司 | 一种快速制备2-溴-5-硝基苯磺酰氯的方法 |
| EP4574144A1 (en) * | 2023-12-19 | 2025-06-25 | Gongwin Biopharm Co., Ltd. | Method for treating peripheral nerve sheath tumor |
| WO2025137508A1 (en) * | 2023-12-22 | 2025-06-26 | Cyteir Therapeutics, Inc. | Solid forms of cyclohexyl thiazolyl phenyl carbamate and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO1992010588A1 (en) | 1990-12-06 | 1992-06-25 | Affymax Technologies N.V. | Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| RU2446796C2 (ru) * | 2006-12-26 | 2012-04-10 | Фармасайкликс, Инк. | Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии |
| US8759366B2 (en) | 2009-12-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Aminopyrimidines as SYK inhibitors |
| WO2014085545A1 (en) * | 2012-11-30 | 2014-06-05 | The University Of Chicago | Methods and compositions involving rad51 inhibitors |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| US10421753B2 (en) * | 2015-03-02 | 2019-09-24 | The Regents Of The University Of California | RAD51 inhibitors and uses thereof |
| WO2016196955A1 (en) * | 2015-06-04 | 2016-12-08 | Drexel University | Inhibitors of RAD52 Recombination Protein and Methods Using Same |
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| CN111542521B (zh) * | 2017-09-11 | 2024-02-23 | 赛泰尔治疗公司 | Rad51抑制剂 |
| BR112021017336A2 (pt) | 2019-03-12 | 2021-11-09 | Cyteir Therapeutics Inc | Inibidores de rad51 |
| PH12021552205A1 (en) * | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
-
2018
- 2018-09-11 CN CN201880072664.5A patent/CN111542521B/zh active Active
- 2018-09-11 US US16/127,229 patent/US10590122B2/en active Active
- 2018-09-11 HU HUE18782257A patent/HUE059969T2/hu unknown
- 2018-09-11 IL IL273156A patent/IL273156B/en unknown
- 2018-09-11 JP JP2020514206A patent/JP7265537B2/ja active Active
- 2018-09-11 DK DK18782257.2T patent/DK3681884T3/da active
- 2018-09-11 SG SG11202002069WA patent/SG11202002069WA/en unknown
- 2018-09-11 AU AU2018328818A patent/AU2018328818C1/en active Active
- 2018-09-11 IL IL293332A patent/IL293332B2/en unknown
- 2018-09-11 MX MX2020002745A patent/MX2020002745A/es unknown
- 2018-09-11 SI SI201830740T patent/SI3681884T1/sl unknown
- 2018-09-11 TW TW107131953A patent/TWI791608B/zh active
- 2018-09-11 EP EP18782257.2A patent/EP3681884B1/en active Active
- 2018-09-11 BR BR112020004828-3A patent/BR112020004828A2/pt unknown
- 2018-09-11 EP EP22175891.5A patent/EP4112616A1/en active Pending
- 2018-09-11 SG SG10202107087YA patent/SG10202107087YA/en unknown
- 2018-09-11 ES ES18782257T patent/ES2925218T3/es active Active
- 2018-09-11 CA CA3075062A patent/CA3075062A1/en active Pending
- 2018-09-11 WO PCT/US2018/050391 patent/WO2019051465A1/en not_active Ceased
- 2018-09-11 KR KR1020207010585A patent/KR102718671B1/ko active Active
- 2018-09-11 PL PL18782257.2T patent/PL3681884T3/pl unknown
- 2018-09-11 PT PT187822572T patent/PT3681884T/pt unknown
- 2018-12-31 US US16/236,894 patent/US10336746B1/en active Active
-
2020
- 2020-01-06 US US16/734,566 patent/US11084812B2/en active Active
- 2020-03-06 PH PH12020550079A patent/PH12020550079A1/en unknown
- 2020-03-11 MX MX2023004221A patent/MX2023004221A/es unknown
-
2021
- 2021-06-11 ZA ZA2021/04029A patent/ZA202104029B/en unknown
- 2021-06-30 US US17/363,099 patent/US20220056022A1/en not_active Abandoned
-
2024
- 2024-08-29 US US18/818,708 patent/US20250136591A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004221A (es) | Inhibidores de rad51. | |
| PH12021552147A1 (en) | Rad51 inhibitors | |
| ZA202311311B (en) | Anti-bcma heavy chain-only antibodies | |
| MX2025012712A (es) | Composiciones utiles para el tratamiento de hemoglobinopatias | |
| ZA201605715B (en) | Cyclopropylamines as lsd1 inhibitors | |
| MX2024014319A (es) | Anticuerpos anti-bcma unicamente de cadena pesada | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| PH12017501817B1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
| PH12021552205A1 (en) | Combinations of rad51 and parp inhibitors | |
| AU2016263598A8 (en) | Methods and kits for treating depression | |
| MX2016004570A (es) | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| MX373549B (es) | Derivado de pirazol amida. | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| NZ746609A (en) | Ilt7 binding molecules and methods of using the same | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| MX2020000367A (es) | Inhibidores de rad51. | |
| MX2016009663A (es) | Derivados de icariina. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| GB2569488A (en) | PD-1 specific aptamers | |
| PH12019500479A1 (en) | Compositions for treating dementia | |
| EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| MX383313B (es) | Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion |